Béatrice Berçot1, Laurent Poirel, Laurent Dortet, Patrice Nordmann. 1. Service de Bactériologie-Virologie, INSERM U914 'Emerging Resistance to Antibiotics', Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine et Université Paris-Sud, K.-Bicêtre, Paris, France. beatrice.bercot@lrb.aphp.fr
Abstract
OBJECTIVES: To analyse the in vitro activity of colistin, fosfomycin and tigecycline alone or in combination against enterobacterial NDM-1 producers. METHODS: MIC values of colistin, fosfomycin and tigecycline were determined for 28 NDM-1-producing enterobacterial isolates. In vitro synergy combination testing was performed for eight clinical isolates and one Escherichia coli transconjugant (six being susceptible to the three antibiotics) using microdilution and chequerboard techniques. RESULTS: MICs of colistin, fosfomycin and tigecycline were determined, showing that one-third of NDM-1-producing isolates were resistant or intermediate to at least one of the three drugs. Nevertheless, in vitro synergistic activity was observed for colistin plus fosfomycin and colistin plus tigecycline in very rare cases. CONCLUSIONS: Synergistic activity was observed for colistin and fosfomycin, and colistin and tigecycline in rare cases, most of the interactions being indifferent.
OBJECTIVES: To analyse the in vitro activity of colistin, fosfomycin and tigecycline alone or in combination against enterobacterial NDM-1 producers. METHODS: MIC values of colistin, fosfomycin and tigecycline were determined for 28 NDM-1-producing enterobacterial isolates. In vitro synergy combination testing was performed for eight clinical isolates and one Escherichia coli transconjugant (six being susceptible to the three antibiotics) using microdilution and chequerboard techniques. RESULTS: MICs of colistin, fosfomycin and tigecycline were determined, showing that one-third of NDM-1-producing isolates were resistant or intermediate to at least one of the three drugs. Nevertheless, in vitro synergistic activity was observed for colistin plus fosfomycin and colistin plus tigecycline in very rare cases. CONCLUSIONS: Synergistic activity was observed for colistin and fosfomycin, and colistin and tigecycline in rare cases, most of the interactions being indifferent.
Authors: Sun Young Cho; Cheol-In Kang; Doo Ryeon Chung; Kyong Ran Peck; Jae-Hoon Song; Jun Ho Jang Journal: Antimicrob Agents Chemother Date: 2012-09 Impact factor: 5.191
Authors: Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas Journal: Clin Microbiol Rev Date: 2016-04 Impact factor: 26.132
Authors: Mohammed Ali M Marie; Lakshmana Gowda Krishnappa; Alhusain J Alzahrani; Murad A Mubaraki; Abdullah A Alyousef Journal: Bosn J Basic Med Sci Date: 2015-10-14 Impact factor: 3.363